These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

308 related items for PubMed ID: 17224915

  • 1. Association of the mu-opioid receptor gene with smoking cessation.
    Munafò MR, Elliot KM, Murphy MF, Walton RT, Johnstone EC.
    Pharmacogenomics J; 2007 Oct; 7(5):353-61. PubMed ID: 17224915
    [Abstract] [Full Text] [Related]

  • 2. Genetic variation in mu-opioid-receptor-interacting proteins and smoking cessation in a nicotine replacement therapy trial.
    Ray R, Jepson C, Wileyto EP, Dahl JP, Patterson F, Rukstalis M, Pinto A, Berrettini W, Lerman C.
    Nicotine Tob Res; 2007 Nov; 9(11):1237-41. PubMed ID: 17978999
    [Abstract] [Full Text] [Related]

  • 3. The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial.
    Lerman C, Wileyto EP, Patterson F, Rukstalis M, Audrain-McGovern J, Restine S, Shields PG, Kaufmann V, Redden D, Benowitz N, Berrettini WH.
    Pharmacogenomics J; 2004 Nov; 4(3):184-92. PubMed ID: 15007373
    [Abstract] [Full Text] [Related]

  • 4. A randomized trial of nicotine replacement therapy in combination with reduced-nicotine cigarettes for smoking cessation.
    Becker KM, Rose JE, Albino AP.
    Nicotine Tob Res; 2008 Jul; 10(7):1139-48. PubMed ID: 18629723
    [Abstract] [Full Text] [Related]

  • 5. Family support and employment as predictors of smoking cessation success: a randomized, double-blind, placebo-controlled trial of nicotine sublingual tablets in chinese smokers.
    Sun HQ, Guo S, Chen DF, Jiang ZN, Liu Y, Di XL, Yang FD, Zhang XY, Kosten TR, Lu L.
    Am J Drug Alcohol Abuse; 2009 Jul; 35(3):183-8. PubMed ID: 19462302
    [Abstract] [Full Text] [Related]

  • 6. Which smokers are helped to give up smoking using transdermal nicotine patches? Results from a randomized, double-blind, placebo-controlled trial.
    Yudkin PL, Jones L, Lancaster T, Fowler GH.
    Br J Gen Pract; 1996 Mar; 46(404):145-8. PubMed ID: 8731618
    [Abstract] [Full Text] [Related]

  • 7. The smoking cessation efficacy of varying doses of nicotine patch delivery systems 4 to 5 years post-quit day.
    Daughton DM, Fortmann SP, Glover ED, Hatsukami DK, Heatley SA, Lichtenstein E, Repsher L, Millatmal T, Killen JD, Nowak RT, Ullrich F, Patil KD, Rennard SI.
    Prev Med; 1999 Feb; 28(2):113-8. PubMed ID: 10048102
    [Abstract] [Full Text] [Related]

  • 8. Nicotine dependence, psychological distress and personality traits as possible predictors of smoking cessation. Results of a double-blind study with nicotine patch.
    Cosci F, Corlando A, Fornai E, Pistelli F, Paoletti P, Carrozzi L.
    Addict Behav; 2009 Jan; 34(1):28-35. PubMed ID: 18804918
    [Abstract] [Full Text] [Related]

  • 9. Relationship between adherence to daily nicotine patch use and treatment efficacy: secondary analysis of a 10-week randomized, double-blind, placebo-controlled clinical trial simulating over-the-counter use in adult smokers.
    Shiffman S, Sweeney CT, Ferguson SG, Sembower MA, Gitchell JG.
    Clin Ther; 2008 Oct; 30(10):1852-8. PubMed ID: 19014840
    [Abstract] [Full Text] [Related]

  • 10. The influence of offering free transdermal nicotine patches on quit rates in a local health department's smoking cessation program.
    Alberg AJ, Stashefsky Margalit R, Burke A, Rasch KA, Stewart N, Kline JA, Ernst PA, Avey A, Hoffman SC.
    Addict Behav; 2004 Dec; 29(9):1763-78. PubMed ID: 15530720
    [Abstract] [Full Text] [Related]

  • 11. A controlled trial of naltrexone augmentation of nicotine replacement therapy for smoking cessation.
    O'Malley SS, Cooney JL, Krishnan-Sarin S, Dubin JA, McKee SA, Cooney NL, Blakeslee A, Meandzija B, Romano-Dahlgard D, Wu R, Makuch R, Jatlow P.
    Arch Intern Med; 2006 Mar 27; 166(6):667-74. PubMed ID: 16567607
    [Abstract] [Full Text] [Related]

  • 12. Smokers deprived of cigarettes for 72 h: effect of nicotine patches on craving and withdrawal.
    Teneggi V, Tiffany ST, Squassante L, Milleri S, Ziviani L, Bye A.
    Psychopharmacology (Berl); 2002 Nov 27; 164(2):177-87. PubMed ID: 12404080
    [Abstract] [Full Text] [Related]

  • 13. Association of COMT Val108/158Met genotype with smoking cessation.
    Munafò MR, Johnstone EC, Guo B, Murphy MF, Aveyard P.
    Pharmacogenet Genomics; 2008 Feb 27; 18(2):121-8. PubMed ID: 18192898
    [Abstract] [Full Text] [Related]

  • 14. Lack of association of OPRM1 genotype and smoking cessation.
    Munafò MR, Johnstone EC, Aveyard P, Marteau T.
    Nicotine Tob Res; 2013 Mar 27; 15(3):739-44. PubMed ID: 22990223
    [Abstract] [Full Text] [Related]

  • 15. A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia.
    Evins AE, Cather C, Culhane MA, Birnbaum A, Horowitz J, Hsieh E, Freudenreich O, Henderson DC, Schoenfeld DA, Rigotti NA, Goff DC.
    J Clin Psychopharmacol; 2007 Aug 27; 27(4):380-6. PubMed ID: 17632223
    [Abstract] [Full Text] [Related]

  • 16. Nicotine replacement therapy for long-term smoking cessation: a meta-analysis.
    Etter JF, Stapleton JA.
    Tob Control; 2006 Aug 27; 15(4):280-5. PubMed ID: 16885576
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Efficacy of nicotine patch in smokers with a history of alcoholism.
    Hughes JR, Novy P, Hatsukami DK, Jensen J, Callas PW.
    Alcohol Clin Exp Res; 2003 Jun 27; 27(6):946-54. PubMed ID: 12824815
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.